RBC Capital Reiterates Outperform on ResMed, Maintains $284 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Craig Wong-Pan has reiterated his 'Outperform' rating on ResMed (NYSE:RMD) and maintained a price target of $284.
August 04, 2023 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ResMed's stock is likely to be positively impacted by RBC Capital's reiterated 'Outperform' rating and maintained price target of $284.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiterated 'Outperform' rating and maintained price target by RBC Capital indicates a positive outlook for ResMed, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100